Daré Bioscience Stock Is Trading Higher As Bacterial Vaginosis Candidate Secures FDA Priority Review

  • The FDA has accepted for review Daré Bioscience Inc's DARE marketing application for DARE-BV1 for bacterial vaginosis.
  • Under the priority review, the target goal date is December 7.
  • DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time treatment.
  • The application is supported by positive data from the DARE-BVFREE Phase 3 study, demonstrating 70-81% clinical cure rates from a single vaginal dose of DARE-BV1.
  • Price Action: DARE shares are up 7.45% at $1.73 during the market session on the last check Monday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!